Drug General Information |
Drug ID |
D0K0OT
|
Former ID |
DNC003816
|
Drug Name |
GNF-PF-2224
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C16H24N4O2
|
InChI |
InChI=1S/C16H24N4O2/c1-3-9-19-14-12(15(21)20(10-4-2)16(19)22)17-13(18-14)11-7-5-6-8-11/h11H,3-10H2,1-2H3,(H,17,18)
|
InChIKey |
FFBDFADSZUINTG-UHFFFAOYSA-N
|
PubChem Compound ID |
|
PubChem Substance ID |
586298, 855876, 6679288, 7422377, 7978611, 8150148, 8151091, 11110874, 11113351, 11335352, 11360591, 11363165, 11365727, 11368289, 11372005, 11374834, 11376451, 11461563, 11485531, 11489624, 11490888, 11493042, 11494085, 12014525, 14776308, 14898584, 17404944, 24277697, 24439671, 26613161, 26680127, 26747024, 26751544, 47216654, 47216983, 47216984, 47515529, 47588863, 47589184, 47810974, 47885280, 48110328, 49689246, 49689262, 50027500, 50100192, 50104134, 50104135, 53777487, 53787841
|
Target and Pathway |
Target(s) |
Adenosine A3 receptor |
Target Info |
Inhibitor |
[2]
|
Adenosine A1 receptor |
Target Info |
Inhibitor |
[3]
|
Adenosine A2a receptor |
Target Info |
Inhibitor |
[3]
|
Adenosine A2b receptor |
Target Info |
Inhibitor |
[4]
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
cAMP signaling pathway
|
Sphingolipid signaling pathway
|
Neuroactive ligand-receptor interaction
|
Morphine addictionhsa04015:Rap1 signaling pathway
|
Calcium signaling pathway
|
Vascular smooth muscle contraction
|
Parkinson's disease
|
Alcoholismhsa04015:Rap1 signaling pathway
|
Alcoholism
|
NetPath Pathway
|
TCR Signaling Pathway
|
RANKL Signaling PathwayNetPath_7:TGF_beta_Receptor Signaling Pathway
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
Pathway Interaction Database
|
HIF-2-alpha transcription factor networkcmyb_pathway:C-MYB transcription factor network
|
PathWhiz Pathway
|
Intracellular Signalling Through Adenosine Receptor A2a and AdenosinePW000446:Intracellular Signalling Through Adenosine Receptor A2b and Adenosine
|
Reactome
|
Adenosine P1 receptors
|
G alpha (i) signalling eventsR-HSA-417973:Adenosine P1 receptors
|
G alpha (i) signalling eventsR-HSA-187024:NGF-independant TRKA activation
|
G alpha (s) signalling events
|
Surfactant metabolismR-HSA-417973:Adenosine P1 receptors
|
Surfactant metabolism
|
WikiPathways
|
Nucleotide GPCRs
|
GPCRs, Class A Rhodopsin-like
|
GPCRs, OtherWP80:Nucleotide GPCRs
|
GPCR ligand binding
|
GPCR downstream signalingWP80:Nucleotide GPCRs
|
Monoamine Transport
|
NGF signalling via TRKA from the plasma membrane
|
GPCR downstream signaling
|
References |
REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 386). |
---|
REF 2 | Bioorg Med Chem. 2010 Nov 15;18(22):7890-9. Epub 2010 Sep 22.Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as selective human A(1) adenosine receptor ligands. |
---|
REF 3 | Eur J Med Chem. 2010 May;45(5):1739-45. Epub 2010 Jan 14.Synthesis and theoretical studies on energetics of novel N- and O- perfluoroalkyl triazole tagged thienopyrimidines--their potential as adenosine receptor ligands. |
---|
REF 4 | Discovery of FK453, a novel non-xanthine adenosine A1 receptor antagonist, Bioorg. Med. Chem. Lett. 6(17):2059-2062 (1996). |